-

Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference, both happening alongside the J.P. Morgan Healthcare Conference in San Francisco next week.

Eddie Martucci, Akili’s Co-Founder and Chief Executive Officer, will represent the company and Digital Therapeutics Alliance (DTA) as a panelist on the Biotech Showcase Future Panel: Digital Therapeutics in The Next Decade, scheduled for January 11 at 12:00 p.m. (Eastern Time).

Company leaders will also meet with investors attending the J.P. Morgan Healthcare Conference.

About Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili’s approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

Contacts

Investors:
Joshua Young
VP, Investor Relations
jyoung@akiliinteractive.com

Media:
Susannah Wesley-Ahlschwede
VP, Communications
swesley@akiliinteractive.com

Akili, Inc.

NASDAQ:AKLI
Details
Headquarters: Boston, MA
CEO: Eddie Martucci
Employees: 80-90
Organization: PRI

Release Versions

Contacts

Investors:
Joshua Young
VP, Investor Relations
jyoung@akiliinteractive.com

Media:
Susannah Wesley-Ahlschwede
VP, Communications
swesley@akiliinteractive.com

More News From Akili, Inc.

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD). Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who...

Akili Reports First Quarter 2024 Financial Results and Provides Business Update

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress. As announced in late April 2024, the Company’s board of directors has initiated a process that is currently ongoing to evaluate potential strategic alternatives to maximize shareholder value. “We are working expeditiously with our board of directors and our external advisors and look forwar...

Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today provided several corporate updates, including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company. Under the terms of the amended agreement, Shionogi has canceled and forgiven a $5.0 million long-term debt obligation and agreed to make certain payments for SDT-001 (the Japanese, localized version of Akili’s AKL-T01 di...
Back to Newsroom